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Ottawa, Ontario, Canada
O B J E C T I V E S We sought the incremental prognostic value of coronary computed tomography
angiography (CTA) in coronary artery bypass graft (CABG) patients.
B A C KG ROUND Coronary CTA is a noninvasive and accurate tool for the detection of obstructive
coronary artery disease, and coronary CTA appears to have prognostic value in patients without previous
revascularization. However, the prognostic value of coronary CTA to predict major adverse cardiac
events in CABG patients is unclear.
METHOD S Consecutive CABG patients were prospectively enrolled and cardiac risk was calculated
using the National Cholesterol Evaluation Program/Adult Treatment Panel III. Using the severity of native
coronary artery disease and graft disease, the number of unprotected coronary territories (UCTs) (0, 1,
2, or 3) was calculated. Patients were followed for cardiac death and nonfatal myocardial infarction. All
events were conﬁrmed with death certiﬁcates or medical records and reviewed by a clinical events
committee.
R E S U L T S Between February 2006 and March 2009, 250 consecutive patients were enrolled and
followed for a mean of 20.8  10.1 months. At follow-up, 23 patients (9.2%) had major adverse cardiac
events (15 cardiac deaths and 8 nonfatal MI). The absence of UCTs conferred a good prognosis with an
annual event rate of 2.4%. Conversely, patients with 1, 2, and 3 UCTs had annualized event rates of 5.8%,
11.1%, and 21.7%, respectively. Multivariable analysis showed that UCTs (hazard ratio: 2.08; 95%
conﬁdence interval: 1.40 to 3.10; p  0.001) was a predictor of major adverse cardiac events when
adjusted for clinical variables. Examining the receiver-operator characteristic curves, the area under the
curve increased from 0.61 to 0.76 when UCTs was combined with clinical variables (p  0.001).
CONC L U S I O N S Assessing UCTs with coronary CTA appears to have prognostic value in CABG
patients and is incremental to clinical variables. Coronary CTA appears to be a promising tool for risk
stratiﬁcation of CABG patients. Further multicenter studies using large CABG cohorts are needed to
conﬁrm our ﬁndings. (J Am Coll Cardiol Img 2011;4:496–502) © 2011 by the American College of
Cardiology Foundation
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497oronary computed tomography angiogra-
phy (CTA) is a noninvasive diagnostic
tool useful for the detection of obstructive
coronary artery disease (CAD) and the
ssessment of coronary artery bypass grafts
CABG) (1–13). Coronary CTA has prognostic
alue and predicts all-cause mortality and major
dverse cardiac events (MACE) such as cardiac
See pages 492 and 503
death and nonfatal myocardial infarction (MI)
(14–19). However, previous studies have excluded
patients with a history of coronary revascularization
(14–19). To further support the utility of coronary
CTA in patients with CABG, the prognostic value
of 64-slice coronary CTA in this population re-
quires further investigation.
Studies using invasive coronary angiography have
demonstrated that the completeness of revascular-
ization is an important predictor of outcome and
that the number of arterial territories lacking a
patent graft is a key determinant of mortality (20).
Although coronary CTA can assess coronary and
graft disease, its ability to assess the native arteries
of CABG patients has been questioned (3,21).
Thus, demonstrating the prognostic value of coro-
nary CTA in the CABG population would further
support its clinical use.
The objective of this prospective cohort study is
to understand the potential incremental prognostic
value of coronary CTA in CABG patients.
M E T H O D S
Between February 2006 and March 2009, 269
consecutive CABG patients undergoing coronary
CTA were prospectively enrolled in a Cardiac CTA
Registry and were followed for all-cause death and
MACE (cardiac death and nonfatal MI) (13,14).
The study was approved by the Institutional Hu-
man Research Ethics Board, and all patients pro-
vided written informed consent.
Clinical predictors. A detailed medical history and
aboratory results were recorded at the time of
oronary CTA. Although a validated prognostic
linical model for CABG patients is lacking, age,
ex, hypertension, and diabetes appear to be predic-
ors of late cardiac events in CABG patients
22,23). Therefore, patients’ age, sex, cardiac risk
actors, and symptoms were used to estimate patient
isk using the National Cholesterol Education Pro- sram/Adult Treatment Panel III (NCEP/ATP III)
uidelines and the Morise score (14,24,25).
Coronary CTA. Before image acquisition, metoprolol
r diltiazem (oral and/or intravenous) was admin-
stered, targeting a heart rate of65 beats/min, and
itroglycerin 0.8 mg was administered sublingually
14,26,27). A biphasic timing bolus (15 to 25 ml of
ontrast (Visipaque 320 or Omnipaque 350, GE
ealthcare, Princeton, New Jersey; 40 ml of saline
olution) was used (13,14). A triphasic protocol
100% contrast, 40%/60% contrast/saline solution
50 ml], and saline solution [40 ml]) was used to
cquire the final dataset. The volume and rate of
ontrast were individualized according to scan time
nd patient body habitus (13,14).
Retrospective electrocardiogram-gated datasets
ere acquired with the GE Volume CT (GE
ealthcare, Milwaukee, Wisconsin) (64 0.625-mm
lice collimation, 350-ms gantry rotation, 400 to
00 mA, kilovolt peak 120, and pitch of
.16 to 0.24) (14). Images were recon-
tructed using a slice thickness of 0.625
m with an increment of 0.4 mm using
he cardiac phase(s) with the least amount
f cardiac motion (13,14).
Coronary CTA image analysis. Images were
post-processed using the GE Advantage
Volume Share Workstation (GE Health-
care) and interpreted by expert observers
blinded to all clinical data (14). A 4-point
grading score (normal, mild [50%],
moderate [50% to 69%], severe [70%])
was used for the evaluation of native CAD
and CABG (28). In segments that were
unassessable, forced reading was per-
formed, and readers provided their best educated
guess. Cases with 5 unassessable segments were
excluded from analysis. Significant stenoses were
defined as left main 50% diameter stenosis, other
ative vessel stenosis 70%, or graft stenosis
70%.
Patients were categorized according to the num-
er (0, 1, 2, or 3) of unprotected coronary territories
UCTs) (20). Each patient had 3 coronary territo-
ies, corresponding to each major epicardial artery
left anterior descending artery, circumflex artery or
rtery supplying the posterior descending artery
right coronary artery or circumflex artery]) and
heir corresponding branches (diagonal and mar-
inal arteries). A coronary territory was deemed
nprotected if: 1) an ungrafted native coronary
rtery had a significant stenosis; 2) a significant
A B B
A N D
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graft
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angio
MACE
event
MI
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Chole
Adult
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498insertion; or 3) a native artery and its graft both
had significant stenoses (20). The left main was
assigned 2 coronary territories in right dominant
system, but 3 coronary territories when left dom-
inant. Similarly, the circumflex artery was as-
signed 2 territories when the native coronary
system was left dominant.
Patient follow-up. Patient follow-up was performed
(at 6-month intervals) by telephone interview by
trained research staff blinded to all clinical data. All
events were confirmed with death records, hospital
records, or correspondence with treating physicians.
A clinical events committee (blinded to the results
of the coronary CTA) reviewed all events.
Outcome measures. The primary outcome measure
as a composite of cardiac death and nonfatal MI.
ll deaths were reviewed and classified as cardiac or
oncardiac. Deaths were considered cardiac when
he primary cause of death was related to myocar-
ial ischemia/infarction, heart failure or cardiac
rrhythmia, and when a noncardiac cause of death
ould not be identified (29). Nonfatal MI was
efined as myocardial ischemia resulting in abnor-
al cardiac biomarkers (99th percentile of the
pper normal limits) (30).
Statistical analysis. Statistical analyses were performed
using SAS software version 9.2 (SAS Institute Inc.,
Cary, North Carolina), and statistical significance was
defined as p  0.05. Continuous variables were
presented as means and SDs, and categorical variables
were presented as frequencies with percentages.
The prognostic value of UCTs was assessed for
univariable association as well as multivariable as-
sociation with MACE. All unadjusted comparisons
of cardiac events were performed using log-rank
tests. For risk-adjusted analysis, a multivariable Cox
proportional hazard model was used to assess the
independent prognostic value of UCTs adjusted for
clinical variables (NCEP/ATP III) and created
adjusted survival curves. Model overfitting was con-
sidered, and the proportional hazards assumption
was met. The incremental value of UCTs was
calculated by defining the clinical variables model
followed by the addition of UCTs. The area under
receiver-operator characteristic curves (95% confi-
dence intervals) was compared to evaluate the dis-
crimination ability of UCTs over clinical variables
to predict MACE.
R E S U L T S
Study population. Over an enrollment period of 37
months, 4,536 consecutive patients underwent cor-onary CTA with a total of 4,508 patients (99.4%)
prospectively enrolled in the University of Ottawa
Heart Institute Cardiac CTA Registry. Of these,
269 had previous CABG surgery and met the
inclusion criteria for this study. A total of 10
patients were excluded from analysis for 5 unas-
sessable segments. Follow-up was available for 250
patients (96.5%) with 9 patients lost to follow-up
(Table 1). The baseline characteristics of the pa-
tients lost to follow-up were similar to those with
follow-up, except those lost to follow-up were
younger and were more likely to have atypical chest
pain or dyspnea.
Univariable analysis of baseline characteristics with
MACE. Univariable analysis of baseline characteris-
ics is summarized in Table 2. Patients with
Table 1. Characteristics of Patients With Follow-Up (n  250)
Mean follow-up, months 20.8 10.1
Age, yrs 65.4 9.5
Men 200 (80.0)
Body mass index, kg/m2 29.5 5.7
Cardiac risk factors
Smoker/ex-smoker 175 (70.0)
Hypertension 157 (62.8)
Dyslipidemia 235 (94.0)
Diabetes 87 (34.8)
Family history of CAD 136 (54.4)
Indications for study
Chest pain 150 (60.0)
Nonanginal chest pain 22 (8.8)
Atypical angina 29 (11.6)
Typical angina 99 (39.6)
Dyspnea 55 (22.0)
Morise score 14.9 2.8
NCEP/ATP III risk
Low risk 3 (1.2)
Intermediate risk 59 (23.6)
High risk 188 (75.2)
Unprotected coronary territories
0 128 (51.2)
1 74 (29.6)
2 37 (14.8)
3 11 (4.4)
Left ventricular ejection fraction, %* 57.9 15.1
Imaging parameters
Imaging heart rate, beats/min 57.9 6.9
Contrast infusion rate, ml/s 6.2 0.9
Total contrast volume, ml 125.3 20.4
Effective dose, mSv† 23.2 5.2
Values are mean  SD or n (%). *Left ventricular ejection fraction could only
be accurately measured in 233 patients. †Effective dose (mSv)  dose length
product  0.014.
CAD  coronary artery disease; NCEP/ATP III  National CholesterolEducation Program/Adult Treatment Program III.
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499MACE were older, had a higher Morise score, and
a greater proportion were in the NCEP/ATP III
high-risk category.
UCTs and MACE. The rates of MACE increased
ith the increasing number of UCTs and were
bserved in a total of 3.9%, 9.5%, 16.2%, and 45.5%
f patients with 0, 1, 2, and 3 UCTs, respectively
Table 3). The absence of UCTs conferred a good
rognosis with an annual event rate of 2.4%. Con-
ersely, patients with 1, 2, and 3 UCTs had annu-
lized event rates of 5.8%, 11.1%, and 21.7%,
espectively.
Risk-adjusted Cox models. For the risk-adjusted
nalysis, the NCEP/ATP III was used as the
linical variable because it combined age, sex, and
ardiac risk factors into a single measure. A multi-
ariable Cox model demonstrated that UCTs (haz-
rd ratio: 2.08; 95% confidence interval: 1.40 to
.10; p  0.001), was an independent predictor for
ACE adjusted for the clinical variables (Fig. 1,
able 4).
Incremental value analysis. The discrimination abil-
ity of UCTs over NCEP/ATP III was evaluated
using receiver-operator characteristic curves (Fig. 2).
The area under the curve for the clinical variable
only was 0.61 (95% confidence interval: 0.56 to
0.66), with a significant increase to 0.76 (95%
confidence interval: 0.66 to 0.86) when UCTs was
added (p  0.001).
D I S C U S S I O N
To our knowledge, the prognostic value of coro-
nary CTA in CABG patients has not been
previously reported. The results of our study
suggest that coronary CTA assessment of UCTs
is of prognostic value and is incremental to
clinical measures.
Prognostic value of coronary CTA. The diagnostic
accuracy and prognostic value of coronary CTA
have been well studied but have focused on patients
with suspected CAD and those without a history of
coronary revascularization (1,14–16,31,32). Be-
cause these studies excluded CABG patients, the
prognostic value of coronary CTA in the CABG
population is unknown.
Conversely, the prognostic value of invasive
coronary angiography in CABG patients has
been well studied. Liao et al. (20) developed a
prognostic model for CABG patients and showed
that the graft index and number of protected
coronary territories predicted all-cause death.The ability to translate this model to coronary
CTA is less certain. Because CABG patients
typically have severe native CAD and coronary
calcification, the diagnostic accuracy of coronary
CTA may be suboptimal (3,21). Such a reduction
in diagnostic accuracy may negatively affect the
ability of coronary CTA to determine prognosis
and limit its utility in the CABG population.
Confirming the prognostic value of coronary
CTA would support its potential use in patients
with previous CABG.
Although more complex invasive coronary an-
giography models have significant prognostic power
(20), our UCTs model appears to be feasible with
coronary CTA and simple to adopt into clinical
practice. A simple UCTs score (0, 1, 2, 3) predicts
annual MACE (2.4%, 5.8%, 11.1%, and 21.7%,
respectively).
Table 2. Univariable Analysis of Clinical Characteristics for MAC
No MACE
(n  227)
MACE
(n  23)
Hazard Ratio
(95% CI)
Age, yrs 64.9 9.5 70.3 8.9 1.06 (1.01–1.11)
Male 180 (79.3) 20 (87.0) 1.72 (0.51–5.78)
BMI, kg/m2 29.6 5.7 28.0 4.8 0.94 (0.87–1.02)
Cardiac risk factors
Diabetes 78 (34.4) 9 (39.1) 1.21 (0.52–2.80)
Dyslipidemia 213 (93.8) 22 (95.7) 2.07 (0.28–15.51)
Hypertension 142 (62.6) 15 (65.2) 1.09 (0.46–2.57)
Family history of CAD 121 (53.3) 15 (65.2) 1.75 (0.74–4.13)
Smoker/ex-smoker 156 (68.7) 19 (82.6) 2.13 (0.72–6.26)
Morise score 14.8 3.4 16.1 3.0 1.12 (0.99–1.28)
NCEP/ATP III risk 6.66 (0.92–48.35)
Low 3 (1.3) 0 (0.0)
Intermediate 58 (25.6) 1 (4.3)
High 166 (73.1) 22 (95.7)
Values are mean  SD or n (%), unless otherwise indicated.
BMI  body mass index; CI  conﬁdence interval; MACE  major adverse car
other abbreviations as in Table 1.
Table 3. Number of UCTs and Adverse Cardiac Events (n  250
# of UCTs n
Cardiac
Death
Nonfatal
MI
MACE
Cardiac Death,
Nonfatal MI
Annu
R
0 128 2 (1.6) 3 (2.3) 5 (3.9)
1 74 5 (6.8) 4 (5.4) 7 (9.5)
2 37 4 (10.8) 3 (8.1) 6 (16.2)
3 11 4 (36.4) 3 (27.3) 5 (45.5)
Log-rank p value 0.001 0.003 0.001
Values are n (%).
MImyocardial infarction; UCTs unprotected coronary territories; other abbE
p Value
0.012
0.384
0.159
0.656
0.479
0.846
0.205
0.170
0.081
0.061
diac events;)
al Event
ate, %
2.35
5.80
11.1
21.7
reviation as
in Table 2.
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500Previous coronary CTA prognosis studies have
used different outcome measures. Some have used
all-cause mortality, whereas others have com-
bined softer endpoints such as unstable angina
and coronary revascularization (15–19). One
trength of our study, although small, is the use
f hard cardiac endpoints (cardiac death and
onfatal MI). Although all-cause mortality is an
mportant and valuable outcome measure, coro-
ary CTA alone cannot accurately predict deaths
aused by cancer, sepsis, or trauma. Chow et al.
14) demonstrated that 59% of deaths in a low-
isk coronary CTA population were noncardiac;
herefore, using cardiac endpoints may often be
Figure 1. Risk-Adjusted Event-Free Survival
Risk-adjusted event-free (cardiac death or nonfatal myocardial infar
territories (UCTs) (0 UCTs [blue line], 1 UCTs [green line]), 2 UCTs [r
Table 4. Cox Models for MACE
Models
Hazard Ratio
(95% CI) p Value
Clinical variables
NCEP/ATP III 6.66 (0.92–48.35) 0.061
Clinical  UCTs
NCEP/ATP III 4.81 (0.66–35.22) 0.122
Unprotected coronary
territories
2.08 (1.40–3.10) 0.001
0 1.0 —
1 2.57 (0.81–8.12) 0.108
2 3.57 (1.09–11.77) 0.036
3 10.89 (3.12–37.99) 0.001oAbbreviations as in Tables 2 and 3.preferred. Our results expand on previous litera-
ture by studying a novel population and demon-
strating that coronary CTA may have merit
beyond diagnosis and may be used to risk stratify
symptomatic CABG patients.
Predictors of MACE in CABG patients. The NCEP/
TP III was initially designed and validated in
atients without known CAD; therefore, its utility
n the CABG population is unclear (25). Although
he CABG population is traditionally considered at
igh risk of future cardiovascular events, each
ndividual’s risk may vary. Because studies have
hown that CABG surgery reduces cardiac mor-
ality (22), CABG patients may not be uniformly
t high risk of cardiac events, especially when
ardiac death is used as one of the outcome
easures. Previous work has identified that age,
ex, hypertension, and diabetes are clinical pre-
ictors of late cardiac events in CABG patients
22,23). Because the NCEP/ATP III combines
hese risk factors, it was selected as the primary
linical model for comparison.
It has been recognized that left ventricular ejec-
ion fraction has prognostic and incremental value
ver CAD severity (14). Although left ventricular
jection fraction measures were available for our
opulation, our small sample size limited our ability
o assess the incremental value of ejection fraction
) survival according to the number of unprotected coronary
line], and 3 UCTs [gray line], p  0.001).ctionver UCTs and clinical predictors. Future studies
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501are needed to understand the incremental value of
left ventricular ejection fraction in this patient
population.
The estimated patient radiation dose in our study
(23.2  5.2 mSv) was higher than that in previous
coronary CTA studies. This likely relates to the
greater scan length needed to ensure coverage of
bypass grafts. In addition, many of the patients were
recruited before the availability of prospective
electrocardiogram-gated acquisition at our institu-
tion. Understanding the potential harm of radiation
exposure, the authors stress the importance of
radiation reduction techniques and that such tech-
niques should be used whenever possible.
Study limitations. This was a single-center, prospec-
Figure 2. Receiver-Operator Characteristic Curves
Signiﬁcant differences in the area under the receiver-operator
characteristic curves conﬁrm the incremental value of unpro-
tected coronary territories (area under the curve: 0.76; 95% con-
ﬁdence interval: 0.66 to 0.86) (green line) over clinical variables
(area under the curve: 0.61; 95% conﬁdence interval: 0.56 to
0.66) (red line) (p  0.001).Gervais W, Kenneth N, Kheng- assessment of patnd the results of our study may not necessarily be
ranslatable to the general CABG population or to
opulations at other centers. Although prospec-
ively enrolled, the CABG population was small
ith relatively few events, thus potentially subject-
ng our analysis to overfitting.
Patient follow-up in our study was excellent
96.5%) and similar to previous prognostic stud-
es (33). However, the authors recognize that
ncomplete follow-up (n  9) may result in the
nderreporting of MACE, which could affect our
ndings. In addition, the small numbers of
ACE restricted our ability to assess the incre-
ental value of left ventricular ejection fraction
nd arterial and venous grafts. Further multi-
enter studies using larger CABG cohorts with
xtended follow-up are required.
C O N C L U S I O N S
The assessment of native CAD, CABG, and UCTs
with coronary CTA appears to have independent
and incremental prognostic value over clinical pre-
dictors. Coronary CTA appears to be a promising
tool for risk stratification of CABG patients. Fur-
ther multicenter studies using large CABG cohorts
are needed to confirm our findings.
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